Verifying…
Home / Drug A–Z / Zadiways-250 Tablet

Zadiways-250 Tablet

NAFDAC Reg. No. B4-2491 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
Zadiways-250 Tablet
NAFDAC number
B4-2491
Active ingredient
Azithromycin (Azithromycin Dihydrate)
Strength
250 mg
Form
Tablet
Pack size
1 x 6's
Manufacturer
Not listed
Applicant (holder)
Phillips Pharmaceuticals (Nigeria) Limited
Approved
28 Jan 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
27 Jan 2026
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Zadiways-250 Tablet is on the NAFDAC register with an active registration (B4-2491). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Zadiways-250 Tablet is used for

From the official U.S. FDA label for azithromycin (azithromycin dihydrate), the active ingredient registered with NAFDAC.

What it is used for

Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2) ] Azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: • Acute bacterial exacerbations of chronic bronchitis in adults () • Acute bacterial sinusitis in adults () • Uncomplicated skin and skin structure infections in adults () • Urethritis and ce …

Possible side effects

The following clinically significant adverse reactions are described elsewhere in labeling: • Hypersensitivity [see ] • Hepatotoxicity [see ] • Infantile Hypertrophic Pyloric Stenosis (IHPS) [see ] • QT Prolongation [see Warnings and Precautions (5.4) ] • Cardiovascular Death [see ] • Clostridioides difficile- Associated Diarrhea (CDAD) [see ] • Exacerbation of Myasthenia Gravis [see ] Most common adverse reactions are diarrhea (5 to 14%), nausea (3 to 18%), abdominal pain (3 to 7%), or vomiting (2 to 7%). ( ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. …

Do not use if

• Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. () • Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. () 4.1 Hypersensitivity Azithromycin tablets are contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. …

Warnings

• Serious (including fatal) allergic and skin reactions: Discontinue azithromycin if reaction occurs. () • Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur. () • Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. () • Prolongation of QT interval and cases of torsades de pointes have been reported. …

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) . …

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Zadiways-250 Tablet

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Zadiways-250 Tablet

What is in Zadiways-250 Tablet?

Zadiways-250 Tablet contains Azithromycin (Azithromycin Dihydrate) (250 mg), as tablet, according to its NAFDAC registration record.

Is Zadiways-250 Tablet registered with NAFDAC?

Yes. Zadiways-250 Tablet is listed on the NAFDAC register under registration number B4-2491, and its registration is active as of 28 October 2026.

Has Zadiways-250 Tablet been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Zadiways-250 Tablet in our automatically synced alert list.

How can I check that my pack of Zadiways-250 Tablet is genuine?

Run a free authenticity scan with the NAFDAC number B4-2491, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Zadiways-250 Tablet used for?

Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2) ] Azithromycin is a macrol (Summarised from the official U.S. FDA label for azithromycin (azithromycin dihydrate). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Zadiways-250 Tablet? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.